In a study of acute myeloid leukemia, activated GPR84 can promote disease resistance through the Wnt /β-catenin axis, which targets and modulates the expression of factor KLF7 in non-small cell lung cancer cells [42, 47]. This evidence concerns the gene KLF7 and acute myeloid leukemia.